CO5090830A1 - Poliformo de un agente farmaceutico - Google Patents

Poliformo de un agente farmaceutico

Info

Publication number
CO5090830A1
CO5090830A1 CO99045166A CO99045166A CO5090830A1 CO 5090830 A1 CO5090830 A1 CO 5090830A1 CO 99045166 A CO99045166 A CO 99045166A CO 99045166 A CO99045166 A CO 99045166A CO 5090830 A1 CO5090830 A1 CO 5090830A1
Authority
CO
Colombia
Prior art keywords
poliform
pharmaceutical agent
amino
thiazolyl
methyl
Prior art date
Application number
CO99045166A
Other languages
English (en)
Inventor
John F Bauer
Saleki-Gerha Azita
A Narayanan Bikshandarko
R Chemburkar Sanjay
M Patel Ketan
Harry O Spiwek
Philip E Bauer
A Allen Kimberly
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26817251&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO5090830(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of CO5090830A1 publication Critical patent/CO5090830A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/28—Radicals substituted by nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Abstract

El polimorfo (Forma II) cristalino del (2S,3S,5S)-5-(N-(N-((N-metil-N-((2-isopropil-4-tiazolil)metil)amino)carbonil)-L -valinil)-amino)-2-(N-((5- tiazolil)metoxicarbonil)amino)- 1,6-difenil-3-hidroxihexano con picos característicos en el patrón de difracción de rayos X en pulverizado con valores 2 teta de 8,67° ± 0,1°, 9,88° ± 0,1°, 16,11° ± 0,1°, 16,70° ± 0,1°, 17,36° ± 0,1°, 17,78° ± 0,1°, 18,40° ± 0,1°, 18,93°± 0,1°, 20,07° ± 0,1°, 20,65°± 0,1°, 21,71° ± 0,1°, y 25,38° ± 0,1°.
CO99045166A 1998-07-20 1999-07-16 Poliformo de un agente farmaceutico CO5090830A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11934598A 1998-07-20 1998-07-20
US32609399A 1999-06-04 1999-06-04

Publications (1)

Publication Number Publication Date
CO5090830A1 true CO5090830A1 (es) 2001-10-30

Family

ID=26817251

Family Applications (1)

Application Number Title Priority Date Filing Date
CO99045166A CO5090830A1 (es) 1998-07-20 1999-07-16 Poliformo de un agente farmaceutico

Country Status (30)

Country Link
EP (4) EP1418174B1 (es)
JP (4) JP4815050B2 (es)
KR (3) KR100853371B1 (es)
CN (5) CN1310715B (es)
AR (5) AR019431A1 (es)
AT (3) ATE261947T1 (es)
AU (1) AU768207B2 (es)
BG (4) BG65150B1 (es)
BR (1) BR9912010A (es)
CA (3) CA2510949C (es)
CO (1) CO5090830A1 (es)
CY (2) CY1111600T1 (es)
CZ (2) CZ307116B6 (es)
DE (2) DE69915628T2 (es)
DK (3) DK2017269T3 (es)
ES (3) ES2322759T3 (es)
HK (2) HK1037918A1 (es)
HU (3) HU230150B1 (es)
ID (1) ID27996A (es)
IL (4) IL140492A0 (es)
MY (2) MY145265A (es)
NO (2) NO318385B1 (es)
NZ (2) NZ522690A (es)
PL (2) PL194710B1 (es)
PT (3) PT1418174E (es)
SI (3) SI2017269T1 (es)
SK (3) SK287586B6 (es)
TR (1) TR200100171T2 (es)
TW (3) TWI227713B (es)
WO (1) WO2000004016A2 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6894171B1 (en) 1998-07-20 2005-05-17 Abbott Laboratories Polymorph of a pharmaceutical
MY145265A (en) * 1998-07-20 2012-01-13 Abbott Lab Amorphous ritonavir
MXPA01012478A (es) * 1999-06-04 2003-10-14 Abbott Lab Formulaciones farmaceuticas mejoradas.
EP1395249A1 (en) * 2001-05-25 2004-03-10 Abbott Laboratories Soft elastic capsules comprising ritonavir and/or lopinavir
TWI286476B (en) * 2001-12-12 2007-09-11 Tibotec Pharm Ltd Combination of cytochrome P450 dependent protease inhibitors
US7205413B2 (en) 2002-05-03 2007-04-17 Transform Pharmaceuticals, Inc. Solvates and polymorphs of ritonavir and methods of making and using the same
US8377952B2 (en) * 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
BRPI0401742B8 (pt) 2004-05-13 2021-05-25 Cristalia Produtos Quim Farmaceuticos Ltda composto análogo do ritonavir útil como inibidor de protease retroviral, preparação do composto análogo do ritonavir e composição farmacêutica do composto análogo do ritonavir
WO2006129276A1 (en) * 2005-05-30 2006-12-07 Ranbaxy Laboratories Limited Processes for the preparation of stable polymorphic form i of ritonavir
US20100099885A1 (en) * 2006-10-03 2010-04-22 Mukesh Kumar Sharma Process for the preparation of form i and form ii of ritonavir
CN102898398B (zh) * 2011-07-27 2015-01-14 上海迪赛诺药业有限公司 一种制备i型利托那韦多晶型结晶的方法
US9370578B2 (en) 2012-03-07 2016-06-21 Ratiopharm Gmbh Dosage form comprising lopinavir and ritonavir
HUE027829T2 (en) 2012-03-07 2016-11-28 Ratiopharm Gmbh Dosage forms containing non-crystalline lopinavir and crystalline ritonavir
MX2016002560A (es) 2013-08-29 2016-10-26 Teva Pharma Forma de dosificacion unitaria que comprende emtricitabina, tenofovir, darunavir y ritonavir y un comprimido monolitico que comprende darunavir y ritonavir.
AU2015245217A1 (en) 2014-04-08 2016-10-13 Teva Pharmaceutical Industries Ltd. Unit dosage form comprising Emtricitabine, Tenofovir, Darunavir and Ritonavir
CN106749085B (zh) * 2016-12-23 2019-05-24 东北制药集团股份有限公司 一种制备利托那韦的方法
EP3569225A1 (en) 2018-05-18 2019-11-20 Pharmaceutical Oriented Services Ltd Solid dispersion containing ritonavir
RU2759544C1 (ru) * 2021-01-29 2021-11-15 Общество с ограниченной ответственностью "АМЕДАРТ" Твёрдая фармацевтическая композиция для изготовления перорального терапевтического средства для профилактики и/или лечения ВИЧ-инфекции

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5539122A (en) * 1989-05-23 1996-07-23 Abbott Laboratories Retroviral protease inhibiting compounds
US5354866A (en) 1989-05-23 1994-10-11 Abbott Laboratories Retroviral protease inhibiting compounds
DK0727419T3 (da) * 1992-12-29 2002-06-10 Abbott Lab Mellemprodukter til fremstilling af forbindelser, som inhiberer retroviral protease
IL110752A (en) 1993-09-13 2000-07-26 Abbott Lab Liquid semi-solid or solid pharmaceutical composition for an HIV protease inhibitor
US5559158A (en) 1993-10-01 1996-09-24 Abbott Laboratories Pharmaceutical composition
US5491253A (en) 1993-10-22 1996-02-13 Abbott Laboratories Process for the preparation of a substituted 2,5-diamino-3-hydroxyhexane
IL111991A (en) 1994-01-28 2000-07-26 Abbott Lab Liquid pharmaceutical composition of HIV protease inhibitors in organic solvent
US5567823A (en) * 1995-06-06 1996-10-22 Abbott Laboratories Process for the preparation of an HIV protease inhibiting compound
US6037157A (en) * 1995-06-29 2000-03-14 Abbott Laboratories Method for improving pharmacokinetics
US6160122A (en) 1996-06-28 2000-12-12 Abbott Laboratories Process for the preparation of a disubstituted thiazole
ZA9710071B (en) 1996-11-21 1998-05-25 Abbott Lab Pharmaceutical composition.
MY145265A (en) * 1998-07-20 2012-01-13 Abbott Lab Amorphous ritonavir
DE19856432A1 (de) * 1998-12-08 2000-06-15 Basf Ag Nanopartikuläre Kern-Schale Systeme sowie deren Verwendung in pharmazeutischen und kosmetischen Zubereitungen
MXPA01012478A (es) * 1999-06-04 2003-10-14 Abbott Lab Formulaciones farmaceuticas mejoradas.

Also Published As

Publication number Publication date
CN101259128A (zh) 2008-09-10
SK286388B6 (sk) 2008-09-05
CZ2006533A3 (cs) 2001-05-16
EP2017269A8 (en) 2009-09-30
NO20042393L (no) 2001-01-18
WO2000004016A2 (en) 2000-01-27
CN1502613A (zh) 2004-06-09
CN1310715A (zh) 2001-08-29
ATE425974T1 (de) 2009-04-15
SI1097148T1 (en) 2004-10-31
HUP0103823A3 (en) 2003-05-28
EP1418174A3 (en) 2004-06-23
EP2298751A3 (en) 2011-08-17
DK1418174T3 (da) 2009-05-18
ES2372990T3 (es) 2012-01-30
CA2674800A1 (en) 2000-01-27
BG66140B1 (bg) 2011-07-29
KR20060118022A (ko) 2006-11-17
EP1418174A2 (en) 2004-05-12
DE69915628D1 (en) 2004-04-22
EP1097148A2 (en) 2001-05-09
CN102153524A (zh) 2011-08-17
PL348033A1 (en) 2002-05-06
CZ2001203A3 (en) 2001-05-16
BG109682A (bg) 2007-03-30
SI2017269T1 (sl) 2012-02-29
PT2017269E (pt) 2011-12-20
NO20010298L (no) 2001-01-18
PT1418174E (pt) 2009-06-08
BR9912010A (pt) 2001-04-10
DK2017269T3 (da) 2012-03-05
IL140492A0 (en) 2002-02-10
SK287381B6 (sk) 2010-08-09
HU227540B1 (en) 2011-08-29
BG110080A (bg) 2008-11-28
TW200716550A (en) 2007-05-01
BG65963B1 (bg) 2010-07-30
JP2017061475A (ja) 2017-03-30
KR100853371B1 (ko) 2008-08-22
KR100793046B1 (ko) 2008-01-10
NO20010298D0 (no) 2001-01-18
EP2017269A3 (en) 2009-06-10
JP2010270135A (ja) 2010-12-02
ES2214038T3 (es) 2004-09-01
WO2000004016A3 (en) 2000-03-30
JP4815050B2 (ja) 2011-11-16
KR100740796B1 (ko) 2007-07-20
CZ298188B6 (cs) 2007-07-18
PL194710B1 (pl) 2007-06-29
AU768207B2 (en) 2003-12-04
CN101966180A (zh) 2011-02-09
NO318385B1 (no) 2005-03-14
TR200100171T2 (tr) 2001-05-21
CN1310715B (zh) 2010-11-03
PT1097148E (pt) 2004-05-31
HU230150B1 (hu) 2015-09-28
DE69940616D1 (de) 2009-04-30
JP5732212B2 (ja) 2015-06-10
DK1097148T3 (da) 2004-04-26
EP2017269A2 (en) 2009-01-21
ATE534636T1 (de) 2011-12-15
EP1097148B1 (en) 2004-03-17
CA2337846A1 (en) 2000-01-27
EP2017269A9 (en) 2009-10-14
IL187181A0 (en) 2008-02-09
PL213978B1 (pl) 2013-05-31
NO327320B1 (no) 2009-06-08
SK287586B6 (sk) 2011-03-04
MY121765A (en) 2006-02-28
HU229999B1 (en) 2015-04-28
IL191582A0 (en) 2008-12-29
CY1111600T1 (el) 2015-10-07
KR20010072003A (ko) 2001-07-31
AR044029A2 (es) 2005-08-24
CA2510949A1 (en) 2000-01-27
SK922001A3 (en) 2001-07-10
AR059764A2 (es) 2008-04-30
EP2017269B1 (en) 2011-11-23
HK1121155A1 (en) 2009-04-17
BG105197A (en) 2001-10-31
ID27996A (id) 2001-05-03
CY1112139T1 (el) 2015-11-04
KR20040081137A (ko) 2004-09-20
IL191582A (en) 2016-02-29
TWI227713B (en) 2005-02-11
EP2298751A2 (en) 2011-03-23
HU0800267D0 (en) 2008-06-30
IL140492A (en) 2010-12-30
NZ522690A (en) 2004-04-30
CA2337846C (en) 2006-02-21
CZ307116B6 (cs) 2018-01-24
HK1037918A1 (en) 2002-02-22
EP1418174B1 (en) 2009-03-18
AR059763A2 (es) 2008-04-30
CA2510949C (en) 2009-11-17
DE69915628T2 (de) 2004-08-12
IL187181A (en) 2009-09-01
TWI362382B (en) 2012-04-21
AR049658A2 (es) 2006-08-23
JP2002520410A (ja) 2002-07-09
JP2014074047A (ja) 2014-04-24
ATE261947T1 (de) 2004-04-15
AR019431A1 (es) 2002-02-20
AU5003799A (en) 2000-02-07
SI1418174T1 (sl) 2009-08-31
HU0800266D0 (en) 2008-06-30
TWI271400B (en) 2007-01-21
MY145265A (en) 2012-01-13
HUP0103823A2 (hu) 2002-02-28
NZ509125A (en) 2003-02-28
ES2322759T3 (es) 2009-06-26
BG65150B1 (bg) 2007-04-30

Similar Documents

Publication Publication Date Title
CO5090830A1 (es) Poliformo de un agente farmaceutico
CA2585898A1 (en) Use of (2s,3s,5s)-5-(n-(n-((n-methyl-n-((2-isopropyl-4-thaizolyl)methyl)amino)-carbonyl)valinyl)amino)-2-(n-((5-thiazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane in combination with another protease inhibitor for treating hiv infection
MX9709454A (es) Procedimiento para la preparacion de un compuesto para inhibir proteasa del virus de inmunodeficiencia humana.
AR055734A1 (es) Una formulacion solida de dosificacion farmaceutica
ME00318B (me) Nova kompozicija i njena upotreba
GEP20074047B (en) Pramipexole once-daily dosage form
GEP20063890B (en) Hiv protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis
RU93043528A (ru) Моногидрат 5-(2-(4-(1,2-бензотиазол-3-ил)-1-пиперазинил)этил)-6-хлор-1,3-дигидро-2н-индол-2-он хлоргидрата, способ его получения, фармацевтическая композиция, способ лечения
DK0503440T3 (da) Sumatriptanholdige lægemidler
HK1042897A1 (en) Thiazole and oxazole derivatives and their pharmaceutical use.
RS50937B (sr) Farmaceutska kompozicija koja sadrži metformin i glibenklamid za lečenje šećerne bolesti tipa ii
WO2004030611A3 (en) Non-nucleoside reverse transcriptase inhibitors
MX2007015480A (es) Formulaciones de dosificacion solida de medicamentos narcoticos que tienen adsorcion bucal mejorada.
WO2004094395A3 (en) Biaryl substituted thiazoles, oxazoles and imidazoles as sodium channel blockers
DE69931925D1 (de) 2-chinolonen enthaltende arzneimittel
UA91852C2 (ru) Фармацевтическая дозированная форма, которая содержит метформин и пиоглитазон как активные медикаменты
BG102857A (en) Antimycotic substance-containing and acetate buffer-containing compositions
WO2001035940A3 (en) Pharmaceutical composition comprising a thiazolidinedione-metformin hydrochloride
GEP20043162B (en) Derivatives of Isosorbid Mononitrate, Utilization as Vasodilator Agents with Reduced Tolerance
HRP20231497T1 (hr) Makrociklični antibiotici širokog spektra
WO2002011694A3 (en) COMPOSITIONS AND DOSAGE FORMS FOR APPLICATION IN ORAL CAVITY IN THE TREATMENT OF MYCOSIS
TR200103144T2 (tr) Yeni bileşikler
AU2002343052A1 (en) Rosiglitazone edisylates and their use as antidiabetics
HUP0301137A2 (hu) Dioxo-tiazolidin-só diabetes mellitus kezelésére, eljárás az előállítására és ezt tartalmazó gyógyszerkészítmény
AP1841A (en) A thiazolidinedione derivative and its use as antidiabetic.